首页|铂耐药卵巢癌复发现状及相关因素

铂耐药卵巢癌复发现状及相关因素

扫码查看
目的:分析铂耐药卵巢癌复发现状及相关因素.方法:选取粤北人民医院 2013 年 1 月~2020 年 1 月收治的86 例复发性卵巢癌患者为研究对象,分为对照组(n=66)与观察组(n=20),单因素、多因素Logistic回归分析铂耐药卵巢癌复发的危险因素.结果:Logistic 回归分析:脉管癌栓、初治时腹水量≥1 000 ml、腹水有癌细胞、糖类抗原 125(CA125)≥200 U/ml、FIGO分期、白蛋白(ALB)≤35 g/L、淋巴细胞与单核细胞比值(LMR)<5.12、血小板与淋巴细胞比值(PLR)≥124是卵巢癌复发的危险因素,差异有统计学意义(P<0.05).结论:铂耐药卵巢癌复发与脉管癌栓、初治时腹水量、腹水有癌细胞、FIGO分期、人附睾蛋白 4(HE4)、CA125、AIB、LMR、PLR异常等因素有关,应及早给予针对性处理,最大限度降低复发率.
Status of platinum resistant ovarian cancer recurrence and related factors
Objective To analyze the status and related factors of platinum resistant ovarian cancer recurrence.Method A total of 86 patients with recurrent ovarian cancer admitted to our hospital were selected as research object,they were divided into control group(n=66)and observation group(n=20).Univariate and multivariate logistic regression analysis was conducted to analyze the risk factors of re-current platinum-resistant ovarian cancer.Results Logistic regression analysis:Vascular cancer thrombus,abdominal water≥1 000 ml at initial treatment,ascites with cancer cells,carbohydrate antigen 125(CA125)≥200 U/ml,FIGO staging,albumin(AIB)≤35 g/L,lymphocyte to monocyte ratio(LMR)<5.12,platelet to lymphocyte ratio(PLR)≥124 were the risk of ovarian cancer recurrence risk factor(P<0.05).Conclusion The recurrence of platinum-resistant ovarian cancer is related to vascular cancer embolus,abdominal water volume at initial treatment,cancer cells in ascites,FIGO stage,abnormal HE4,CA125,AIB,LMR,PLR and other factors,which should attract clinical attention and attention,and give early targeted treatment to minimize the recurrence rate.

Platinum resistanceOvarian cancerRelapseCorrelation factor

刘建、廖宗敏、胡红波

展开 >

粤北人民医院妇科,广东 韶关 512026

铂耐药 卵巢癌 复发 相关因素

韶关市科技计划项目韶关市卫生健康科研计划项目

220522154531146Y22004

2024

吉林医学
吉林省人民医院

吉林医学

影响因子:0.926
ISSN:1004-0412
年,卷(期):2024.45(5)
  • 19